HCN Oncology Essentials: Cognitive Decline in Lymphoma | FDA Questions Dosing Requirements | Treating Pediatric AMLSeptember 28, 2021 | Oncology Geriatrics Cognitive Decline Observed Six Months After Chemotherapy in Patients With Lymphoma Publication: ASH Clinical NewsOriginal Source: Journal of the National Care InstituteDesign: Assessment of longitudinal changes in memory, attention, and executive function in men and women with lymphoma (n=248; 62.5% male) prior to and six months after initiation of chemotherapy. A group of age- and sex-matched people without cancer was used as a control arm (n=212; 59% male).Results: At baseline, patients with lymphoma self-reported significantly more issues on the FACT-Cog scale (perceived cognitive impairment [PCI] and total scores) compared with sex-matched controls (p<0.05). In addition, patients with lymphoma reported significantly more attentional difficulty (p=0.01) and significantly greater PCI (p<0.03). Read full article Hematology Dose Optimization of Sotorasib: Is the US Food and Drug Administration Sending a Message? The FDA has required that Amgen compare its approved KRAS-targeted therapy sotorasib (Lumakras) 960-mg dose with a 240-mg dose as one of its accelerated approval post-marketing requirements, a paradigm-shifting event that signals new scrutiny around determining the labeled dose for targeted oncology drugs, which still follow outdated maximum tolerated dose (MTD) principles in cytotoxic agents. Read full article Hematology How I Treat Pediatric Acute Myeloid Leukemia In this series from Blood that tackles four cases studies, the outcomes of AML pediatric patients compared to children with ALL is explored, focusing on the emerging new treatments venetoclax (Venclexta; AbbVie/Genentech), CD33- and CD123-directed CAR T-cell therapy, CD123-directed antibody therapy, and menin inhibitors. Read full article
DIET & NUTRITION 
PATIENT EDUCATION 
OBESITY/WEIGHT MANAGEMENT 
EXERCISE/TRAINING 
LEGAL MATTERS 
GUIDELINES/RECOMMENDATIONS